Here are the 10-K annual reports from Passage Bio, Inc. (PASG) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow PASG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PASG filings page.
Passage Bio files its annual report describing progress on PBFT02, a gene therapy for frontotemporal dementia caused by progranulin deficiency (FTD-GRN) and related neurodegenerative diseases. In a Phase 1/2 trial, Dose 1 of PBFT02 raised cerebrospinal fluid progranulin from below 3.0 ng/mL at baseline to means of 12.4 ng/mL at one month, 19.4 ng/mL at six months, 25.9 ng/mL at 12 months and 23.8 ng/mL at 18 months, above healthy control ranges. Plasma neurofilament light chain, a marker of neurodegeneration, increased 4% at 12 months versus natural-history increases of about 28–29%. Safety data showed treatment-related venous sinus thrombosis and hepatotoxicity at the higher dose, which were asymptomatic and responsive to treatment. The company is now enrolling a lower-dose Cohort 3, extending PBFT02 development into FTD with C9orf72 mutations, and positioning a higher-yield suspension manufacturing process with Catalent for late-stage trials. Passage Bio also highlights an HD program with Gemma Biotherapeutics targeting MSH3 to reduce somatic instability, plus orphan and Fast Track designations for PBFT02 in FTD.